ArticleEMBO molecular medicine2026
IRF7 links HK1-dependent histone lactylation to fibroblast activation and cardiac fibrosis.
Article in EMBO molecular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
8 authors.
Funding
Abstract
In response to various stimuli, quiescent resident cardiac fibroblasts undergo metabolic, morphological, and functional alterations, transitioning into myofibroblasts that mediate cardiac fibrosis. In the present study, we investigated the role of interferon regulatory factor 7 (IRF7) in fibroblast activation and cardiac fibrosis. Knockdown of IRF7 in quiescent cardiac fibroblasts potentiated myofibroblast transition, whereas overexpression of IRF7 suppressed it. Furthermore, targeted deletion of IRF7 in fibroblasts or myofibroblasts exacerbated cardiac fibrosis and impaired heart function in animal models of heart failure. Integrated transcriptomic analysis revealed hexokinase 1 (HK1) as an IRF7 downstream target. Consistently, genetic deletion or pharmacological inhibition of HK1 protected mice from adverse cardiac remodeling. Mechanistically, HK1 contributed to the cellular lactate pool, promoting histone H3K9 lactylation and enabling the transcription of pro-fibrogenic molecules. Finally, the relevance of the IRF7-HK1 axis was verified in human heart specimens. In conclusion, our data unveil an IRF7-HK1 axis that contributes to the metaboloepigenetic reprogramming of fibroblast activation and cardiac fibrosis. Targeting this axis may yield new therapeutic solutions for heart failure intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.